0,1,2
us-gaap:accountspayablecurrent,3102000000,FI2017Q4
us-gaap:accountspayablecurrent,3091000000,FI2018Q3
us-gaap:accountsreceivablenetcurrent,6873000000,FI2017Q4
us-gaap:accountsreceivablenetcurrent,7374000000,FI2018Q3
us-gaap:accountsreceivablenetcurrent,7329000000,FI2018Q3_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:accountsreceivablenetcurrent,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:accountsreceivablenetcurrent,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:accruedincometaxescurrent,708000000,FI2017Q4
us-gaap:accruedincometaxescurrent,759000000,FI2018Q3
us-gaap:accruedincometaxescurrent,754000000,FI2018Q3_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:accumulateddepreciationdepletionandamortizationpropertyplantandequipment,16602000000,FI2017Q4
us-gaap:accumulateddepreciationdepletionandamortizationpropertyplantandequipment,16568000000,FI2018Q3
us-gaap:additionalpaidincapitalcommonstock,39902000000,FI2017Q4
us-gaap:additionalpaidincapitalcommonstock,39762000000,FI2018Q3
us-gaap:allocatedsharebasedcompensationexpensenetoftax,53000000,FD2017Q3QTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,162000000,FD2017Q3YTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,77000000,FD2018Q3QTD
us-gaap:allocatedsharebasedcompensationexpensenetoftax,219000000,FD2018Q3YTD
us-gaap:allowancefordoubtfulaccountsreceivablecurrent,210000000,FI2017Q4
us-gaap:allowancefordoubtfulaccountsreceivablecurrent,229000000,FI2018Q3
us-gaap:amortizationofintangibleassets,9000000,FD2018Q1QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember
us-gaap:amortizationofintangibleassets,17000000,FD2018Q2QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_srt_ProductOrServiceAxis_mrk_LynparzaMember
us-gaap:amortizationofintangibleassets,106000000,FD2018Q2QTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_srt_ProductOrServiceAxis_mrk_AdempasMember
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,4000000,FD2017Q3YTD
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,2000000,FD2018Q3QTD
us-gaap:antidilutivesecuritiesexcludedfromcomputationofearningspershareamount,7000000,FD2018Q3YTD
us-gaap:assets,87872000000,FI2017Q4
us-gaap:assets,85130000000,FI2018Q3
us-gaap:assetscurrent,24766000000,FI2017Q4
us-gaap:assetscurrent,26836000000,FI2018Q3
us-gaap:assetsfairvaluedisclosure,343000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,14970000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,15313000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,432000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,10509000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:assetsfairvaluedisclosure,10941000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,11000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,9000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,3000000,FI2018Q3
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,1000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax,2000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,79000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,7000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,40000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,6000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,9000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,17000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,127000000,FI2018Q3
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,13000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,88000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,8000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,1000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax,17000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,14976000000,FI2017Q4
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1548000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,9837000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,739000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,634000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,2059000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,159000000,FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,10300000000,FI2018Q3
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1300000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,6952000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,546000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,24000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,1448000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsaledebtsecuritiesamortizedcostbasis,30000000,FI2018Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsaleequitysecuritiesaccumulatedgrossunrealizedgainbeforetax,16000000,FI2017Q4
us-gaap:availableforsaleequitysecuritiesaccumulatedgrossunrealizedlossbeforetax,6000000,FI2017Q4
us-gaap:availableforsaleequitysecuritiesamortizedcostbasis,265000000,FI2017Q4
us-gaap:availableforsalesecurities,15183000000,FI2017Q4
us-gaap:availableforsalesecuritiesaccumulatedgrossunrealizedgainbeforetax,27000000,FI2017Q4
us-gaap:availableforsalesecuritiesaccumulatedgrossunrealizedlossbeforetax,85000000,FI2017Q4
us-gaap:availableforsalesecuritiesamortizedcost,15241000000,FI2017Q4
us-gaap:availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsfairvalue,7100000000,FI2018Q3
us-gaap:availableforsalesecuritiesdebtsecurities,14908000000,FI2017Q4
us-gaap:availableforsalesecuritiesdebtsecurities,68000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1476000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9678000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,732000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,547000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1767000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1476000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9678000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,732000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,547000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1835000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1542000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,9806000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,733000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,626000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,2042000000,FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,159000000,FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,10176000000,FI2018Q3
us-gaap:availableforsalesecuritiesdebtsecurities,1271000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,6765000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,538000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1265000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1271000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,6765000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,538000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1265000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecurities,1288000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,6866000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,538000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,23000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,1431000000,FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:availableforsalesecuritiesdebtsecurities,30000000,FI2018Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember
us-gaap:availableforsalesecuritiesdebtsecuritiescurrent,2400000000,FI2018Q3
us-gaap:availableforsalesecuritiesequitysecurities,275000000,FI2017Q4
us-gaap:businessacquisitionpercentageofvotinginterestsacquired,0.935,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businessacquisitionpercentageofvotinginterestsacquired,0.045,FI2017Q4_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationacquisitionoflessthan100percentnoncontrollinginterestfairvalue,25000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsideratio,151000000,FD2017Q3YTD
us-gaap:businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsideratio,144000000,FD2018Q3YTD
us-gaap:businesscombinationcontingentconsiderationliability,891000000,FI2016Q4
us-gaap:businesscombinationcontingentconsiderationliability,945000000,FI2017Q3
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,935000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,852000000,FI2018Q3
us-gaap:businesscombinationcontingentconsiderationliability,852000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliability,852000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:businesscombinationcontingentconsiderationliabilitycurrent,95000000,FI2018Q3
us-gaap:businesscombinationindemnificationassetsamountasofacquisitiondate,37000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcontingentliabil,37000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcurrentassetsoth,32000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcurrentassetsoth,34000000,FI2018Q3_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumeddeferredtaxliabi,102000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedintangibles,297000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:cashandcashequivalentsatcarryingvalue,6092000000,FI2017Q4
us-gaap:cashandcashequivalentsatcarryingvalue,7826000000,FI2018Q3
us-gaap:cashandcashequivalentsatcarryingvalue,7800000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,6515000000,FI2016Q4
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,7901000000,FI2017Q3
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,6096000000,FI2017Q4
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalents,7828000000,FI2018Q3
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincluding,1386000000,FD2017Q3YTD
us-gaap:cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincluding,1732000000,FD2018Q3YTD
us-gaap:cashequivalentsatcarryingvalue,7100000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member
us-gaap:changeinunrealizedgainlossonfairvaluehedginginstruments1,25000000,FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,9000000,FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,5000000,FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,9000000,FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:changeinunrealizedgainlossonhedgediteminfairvaluehedge1,86000000,FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:commonstockdividendspersharedeclared,0.47,FD2017Q3QTD
us-gaap:commonstockdividendspersharedeclared,1.41,FD2017Q3YTD
us-gaap:commonstockdividendspersharedeclared,0.48,FD2018Q3QTD
us-gaap:commonstockdividendspersharedeclared,1.44,FD2018Q3YTD
us-gaap:commonstockparorstatedvaluepershare,0.50,FI2017Q4
us-gaap:commonstockparorstatedvaluepershare,0.50,FI2018Q3
us-gaap:commonstocksharesauthorized,6500000000,FI2017Q4
us-gaap:commonstocksharesauthorized,6500000000,FI2018Q3
us-gaap:commonstocksharesissued,3577000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,828000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,850000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,851000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577103522,FI2017Q4
us-gaap:commonstocksharesissued,3577000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,880000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,907000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstocksharesissued,3577103522,FI2018Q3
us-gaap:commonstocksharesissued,3577000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:commonstocksharesissued,918000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:commonstockvalue,1788000000,FI2017Q4
us-gaap:commonstockvalue,1788000000,FI2018Q3
us-gaap:comprehensiveincomenetoftax,93000000,FD2017Q3QTD
us-gaap:comprehensiveincomenetoftax,3721000000,FD2017Q3YTD
us-gaap:comprehensiveincomenetoftax,1921000000,FD2018Q3QTD
us-gaap:comprehensiveincomenetoftax,4426000000,FD2018Q3YTD
us-gaap:costofgoodsandservicessold,3307000000,FD2017Q3QTD
us-gaap:costofgoodsandservicessold,9472000000,FD2017Q3YTD
us-gaap:costofgoodsandservicessold,3619000000,FD2018Q3QTD
us-gaap:costofgoodsandservicessold,3618000000,FD2018Q3QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:costofgoodsandservicessold,10220000000,FD2018Q3YTD
us-gaap:costofgoodsandservicessold,10202000000,FD2018Q3YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,8000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member
us-gaap:cumulativeeffectofnewaccountingprincipleinperiodofadoption,54000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member
us-gaap:debtandcapitalleaseobligations,24400000000,FI2017Q4
us-gaap:debtandcapitalleaseobligations,23600000000,FI2018Q3
us-gaap:debtandequitysecuritiesgainloss,25000000,FD2017Q3QTD
us-gaap:debtandequitysecuritiesgainloss,74000000,FD2017Q3YTD
us-gaap:debtandequitysecuritiesgainloss,80000000,FD2018Q3QTD
us-gaap:debtandequitysecuritiesgainloss,202000000,FD2018Q3YTD
us-gaap:debtcurrent,3057000000,FI2017Q4
us-gaap:debtcurrent,3656000000,FI2018Q3
us-gaap:debtcurrent,14000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_mrk_AccountingStandardUpdate201712Member
us-gaap:debtcurrent,14000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:debtinstrumentfaceamount,1000000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:debtinstrumentfaceamount,1150000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:debtinstrumentfaceamount,1250000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:debtinstrumentfaceamount,1000000000.0,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:debtinstrumentfairvalue,25600000000,FI2017Q4
us-gaap:debtinstrumentfairvalue,24000000000,FI2018Q3
us-gaap:debtinstrumentinterestratestatedpercentage,0.0185,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.02350,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.0240,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.03875,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.0500,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:debtinstrumentinterestratestatedpercentage,0.013,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:deferredincometaxliabilitiesnet,2219000000,FI2017Q4
us-gaap:deferredincometaxliabilitiesnet,2065000000,FI2018Q3
us-gaap:deferredincometaxesandotherassetscurrent,4299000000,FI2017Q4
us-gaap:deferredincometaxesandotherassetscurrent,3761000000,FI2018Q3
us-gaap:deferredincometaxesandotherassetsnoncurrent,6075000000,FI2017Q4
us-gaap:deferredincometaxesandotherassetsnoncurrent,7500000000,FI2018Q3
us-gaap:deferredtaxliabilitiesundistributedforeignearnings,2000000000,FI2017Q4_us-gaap_TaxPeriodAxis_mrk_A2017TaxCutsandJobsActTCJAMember
us-gaap:definedbenefitplancontributionsbyemployer,325000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,3000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,11000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,2000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,1000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,18000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplancostofprovidingspecialorcontractualterminationbenefitrecognizedduringperio,2000000,FD2018Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedfutureemployercontributionscurrentfiscalyear,375000000,FI2018Q3_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,210000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,101000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,20000000,FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,646000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,292000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,59000000,FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,209000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,106000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,21000000,FD2018Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,634000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,326000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanexpectedreturnonplanassets,63000000,FD2018Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,114000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,44000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,20000000,FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,341000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,127000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,61000000,FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,109000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,43000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,17000000,FD2018Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,324000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,134000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplaninterestcost,52000000,FD2018Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,24000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,31000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,43000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,89000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,32000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,11000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,98000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplannetperiodicbenefitcost,45000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,6000000,FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2018Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,1000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanrecognizednetgainlossduetocurtailments,7000000,FD2018Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,80000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,66000000,FD2017Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,15000000,FD2017Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,234000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,189000000,FD2017Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,43000000,FD2017Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,77000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,56000000,FD2018Q3QTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,15000000,FD2018Q3QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,245000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,181000000,FD2018Q3YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember
us-gaap:definedbenefitplanservicecost,43000000,FD2018Q3YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember
us-gaap:depreciationdepletionandamortization,334000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,3509000000,FD2017Q3YTD
us-gaap:depreciationdepletionandamortization,1036000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,324000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:depreciationdepletionandamortization,3424000000,FD2018Q3YTD
us-gaap:depreciationdepletionandamortization,1006000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:derivativeassetfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangementpoli,33000000,FI2017Q4
us-gaap:derivativeassetfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangementpoli,198000000,FI2018Q3
us-gaap:derivativeassetnotoffsetpolicyelectiondeduction,94000000,FI2017Q4
us-gaap:derivativeassetnotoffsetpolicyelectiondeduction,135000000,FI2018Q3
us-gaap:derivativeassets,130000000,FI2017Q4
us-gaap:derivativeassets,38000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,51000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,39000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,48000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,48000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,80000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,80000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,2000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,130000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,130000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,91000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,39000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,387000000,FI2018Q3
us-gaap:derivativeassets,85000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,175000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,127000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeassets,233000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,233000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,154000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,154000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,387000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,387000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeassets,260000000,FI2018Q3_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeassets,127000000,FI2018Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativecollateralobligationtoreturncash,3000000,FI2017Q4
us-gaap:derivativecollateralobligationtoreturncash,54000000,FI2018Q3
us-gaap:derivativeinstrumentsgainlossreclassificationfromaccumulatedocitoincomeestimatednetamounttob,75000000,FD2018Q3YTD
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,57000000,FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,224000000,FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember
us-gaap:derivativeinstrumentsnotdesignatedashedginginstrumentsgainlossnet,5000000,FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeFutureMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember
us-gaap:derivativeliabilities,217000000,FI2017Q4
us-gaap:derivativeliabilities,71000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,90000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,3000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,1000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,52000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,162000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,162000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,55000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,55000000,FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,217000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,217000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,127000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,90000000,FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,204000000,FI2018Q3
us-gaap:derivativeliabilities,5000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,58000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilities,2000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,1000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,138000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,60000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,60000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,4000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,4000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeOptionMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,140000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,140000000,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,204000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,204000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:derivativeliabilities,146000000,FI2018Q3_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember
us-gaap:derivativeliabilities,58000000,FI2018Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember
us-gaap:derivativeliabilityfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangement,123000000,FI2017Q4
us-gaap:derivativeliabilityfairvalueoffsetagainstcollateralnetofnotsubjecttomasternettingarrangement,69000000,FI2018Q3
us-gaap:derivativeliabilitynotoffsetpolicyelectiondeduction,94000000,FI2017Q4
us-gaap:derivativeliabilitynotoffsetpolicyelectiondeduction,135000000,FI2018Q3
us-gaap:dividendscommonstockcash,1289000000,FD2017Q3QTD
us-gaap:dividendscommonstockcash,1289000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendscommonstockcash,3872000000,FD2017Q3YTD
us-gaap:dividendscommonstockcash,3872000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendscommonstockcash,1284000000,FD2018Q3QTD
us-gaap:dividendscommonstockcash,1284000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendscommonstockcash,3876000000,FD2018Q3YTD
us-gaap:dividendscommonstockcash,3876000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:dividendspayablecurrent,1320000000,FI2017Q4
us-gaap:dividendspayablecurrent,1304000000,FI2018Q3
us-gaap:earningspersharebasic,1.26,FD2017Q3YTD
us-gaap:earningspersharebasic,0.73,FD2018Q3QTD
us-gaap:earningspersharebasic,1.64,FD2018Q3YTD
us-gaap:earningspersharediluted,1.25,FD2017Q3YTD
us-gaap:earningspersharediluted,0.73,FD2018Q3QTD
us-gaap:earningspersharediluted,1.63,FD2018Q3YTD
us-gaap:effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents,438000000,FD2017Q3YTD
us-gaap:effectiveincometaxratecontinuingoperations,1.255,FD2017Q3QTD
us-gaap:effectiveincometaxratecontinuingoperations,0.255,FD2017Q3YTD
us-gaap:effectiveincometaxratecontinuingoperations,0.265,FD2018Q3QTD
us-gaap:effectiveincometaxratecontinuingoperations,0.276,FD2018Q3YTD
us-gaap:employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized,654000000,FI2018Q3
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,23000000,FD2017Q3QTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,70000000,FD2017Q3YTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,14000000,FD2018Q3QTD
us-gaap:employeeservicesharebasedcompensationtaxbenefitfromcompensationexpense,42000000,FD2018Q3YTD
us-gaap:equitysecuritiesfvni,104000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,104000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,378000000,FI2018Q3
us-gaap:equitysecuritiesfvni,196000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvni,196000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:equitysecuritiesfvniunrealizedgain,10000000,FD2018Q3QTD
us-gaap:equitysecuritiesfvniunrealizedgain,60000000,FD2018Q3YTD
us-gaap:equitysecuritieswithoutreadilydeterminablefairvalueamount,749000000,FI2018Q3
us-gaap:equitysecuritieswithoutreadilydeterminablefairvaluedownwardpriceadjustmentannualamount,25000000,FD2018Q3YTD
us-gaap:equitysecuritieswithoutreadilydeterminablefairvalueupwardpriceadjustmentannualamount,199000000,FD2018Q3YTD
us-gaap:escrowdeposit,176000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitypurchases,3000000,FD2017Q3YTD
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitypurchases,8000000,FD2018Q3YTD
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitysettlements,100000000,FD2017Q3YTD
us-gaap:fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitysettlements,235000000,FD2018Q3YTD
us-gaap:finitelivedintangibleassetsnet,1100000000,FI2018Q3_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_BalanceSheetLocationAxis_us-gaap_FiniteLivedIntangibleAssetsMember
us-gaap:finitelivedintangibleassetsnet,266000000,FI2018Q3_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember
us-gaap:finitelivedintangibleassetsnet,468000000,FI2018Q3_srt_ProductOrServiceAxis_mrk_LynparzaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember
us-gaap:foreigncurrencytransactiongainlossbeforetax,6000000,FD2017Q3QTD
us-gaap:gainlossoncontracttermination,420000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:gainlossoncontracttermination,420000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:gainlossrelatedtolitigationsettlement,115000000,D2018Q1Jan
us-gaap:goodwill,156000000,FI2017Q1_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:goodwill,18284000000,FI2017Q4
us-gaap:goodwill,18258000000,FI2018Q3
us-gaap:hedgedliabilitydiscontinuedfairvaluehedgecumulativeincreasedecrease,11000000,FI2017Q4
us-gaap:hedgedliabilitydiscontinuedfairvaluehedgecumulativeincreasedecrease,6000000,FI2018Q3
us-gaap:hedgedliabilityfairvaluehedge,983000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,5146000000,FI2017Q4_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,553000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedge,4503000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtExcludingCurrentMaturitiesMember
us-gaap:hedgedliabilityfairvaluehedgecumulativeincreasedecrease,3000000,FI2018Q3_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember
us-gaap:impairedassetstobedisposedofbymethodotherthansaleamountofimpairmentloss,137000000,FD2018Q3QTD_srt_CounterpartyNameAxis_mrk_SamsungMember
us-gaap:impairmentofintangibleassetsexcludinggoodwill,376000000,FD2017Q3YTD
us-gaap:impairmentofintangibleassetsfinitelived,47000000,FD2017Q3YTD_srt_ProductOrServiceAxis_mrk_IntronAMember
us-gaap:impairmentofintangibleassetsindefinitelivedexcludinggoodwill,245000000,FD2017Q3QTD
us-gaap:impairmentofintangibleassetsindefinitelivedexcludinggoodwill,240000000,FD2017Q3QTD_srt_ProductOrServiceAxis_mrk_UprifosbuvirMember
us-gaap:impairmentofintangibleassetsindefinitelivedexcludinggoodwill,253000000,FD2017Q3YTD
us-gaap:impairmentofintangibleassetsindefinitelivedexcludinggoodwill,240000000,FD2017Q3YTD_srt_ProductOrServiceAxis_mrk_UprifosbuvirMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,200000000,FD2017Q3QTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6388000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,389000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,5906000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,93000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,4642000000,FD2017Q3YTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,107000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,18093000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,1202000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,16657000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,234000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,2665000000,FD2018Q3QTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,55000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6893000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,409000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6479000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,5000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,2665000000,FD2018Q3QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6097000000,FD2018Q3YTD
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,19476000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,1273000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,18109000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,94000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest,6085000000,FD2018Q3YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incomelossfromequitymethodinvestments,18000000,FD2017Q3QTD
us-gaap:incomelossfromequitymethodinvestments,23000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incomelossfromequitymethodinvestments,11000000,FD2017Q3YTD
us-gaap:incomelossfromequitymethodinvestments,16000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incomelossfromequitymethodinvestments,81000000,FD2018Q3QTD
us-gaap:incomelossfromequitymethodinvestments,85000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incomelossfromequitymethodinvestments,93000000,FD2018Q3YTD
us-gaap:incomelossfromequitymethodinvestments,101000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:incometaxexpensebenefit,251000000,FD2017Q3QTD
us-gaap:incometaxexpensebenefit,1186000000,FD2017Q3YTD
us-gaap:incometaxexpensebenefit,707000000,FD2018Q3QTD
us-gaap:incometaxexpensebenefit,707000000,FD2018Q3QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incometaxexpensebenefit,1682000000,FD2018Q3YTD
us-gaap:incometaxexpensebenefit,1679000000,FD2018Q3YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:incometaxespaid,2800000000,FD2017Q3QTD_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember
us-gaap:incometaxespaid,2800000000,FD2017Q3YTD_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember
us-gaap:increasedecreaseinoperatingcapital,5259000000,FD2017Q3YTD
us-gaap:increasedecreaseinoperatingcapital,2034000000,FD2018Q3YTD
us-gaap:intangibleassetsnetexcludinggoodwill,14183000000,FI2017Q4
us-gaap:intangibleassetsnetexcludinggoodwill,12175000000,FI2018Q3
us-gaap:interestexpense,189000000,FD2017Q3QTD
us-gaap:interestexpense,189000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,564000000,FD2017Q3YTD
us-gaap:interestexpense,564000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,190000000,FD2018Q3QTD
us-gaap:interestexpense,190000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestexpense,569000000,FD2018Q3YTD
us-gaap:interestexpense,569000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:interestpaid,505000000,FD2017Q3YTD
us-gaap:interestpaid,535000000,FD2018Q3YTD
us-gaap:inventoryfinishedgoods,1334000000,FI2017Q4
us-gaap:inventoryfinishedgoods,1585000000,FI2018Q3
us-gaap:inventorygross,6238000000,FI2017Q4
us-gaap:inventorygross,6720000000,FI2018Q3
us-gaap:inventoryliforeserve,10000000,FI2018Q3
us-gaap:inventorynet,5096000000,FI2017Q4
us-gaap:inventorynet,5416000000,FI2018Q3
us-gaap:inventorynet,19000000,FI2018Q3_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:inventorynet,5435000000,FI2018Q3_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:inventorynoncurrent,1187000000,FI2017Q4
us-gaap:inventorynoncurrent,80000000,FI2017Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember
us-gaap:inventorynoncurrent,1100000000,FI2017Q4_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember
us-gaap:inventorynoncurrent,1294000000,FI2018Q3
us-gaap:inventorynoncurrent,3000000,FI2018Q3_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoriesProducedinPreparationforProductLaunchesMember
us-gaap:inventorynoncurrent,1300000000,FI2018Q3_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember
us-gaap:inventoryworkinprocessandrawmaterials,4703000000,FI2017Q4
us-gaap:inventoryworkinprocessandrawmaterials,4933000000,FI2018Q3
us-gaap:investmentincomeinterest,90000000,FD2017Q3QTD
us-gaap:investmentincomeinterest,90000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,284000000,FD2017Q3YTD
us-gaap:investmentincomeinterest,284000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,92000000,FD2018Q3QTD
us-gaap:investmentincomeinterest,92000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:investmentincomeinterest,257000000,FD2018Q3YTD
us-gaap:investmentincomeinterest,257000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:liabilitiesandstockholdersequity,87872000000,FI2017Q4
us-gaap:liabilitiesandstockholdersequity,85130000000,FI2018Q3
us-gaap:liabilitiescurrent,18614000000,FI2017Q4
us-gaap:liabilitiescurrent,18586000000,FI2018Q3
us-gaap:liabilitiesfairvaluedisclosure,217000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,935000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,1152000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,204000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,852000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:liabilitiesfairvaluedisclosure,1056000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:litigationreserve,160000000,FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember
us-gaap:litigationreserve,150000000,FI2018Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember
us-gaap:litigationsettlementamountawardedfromotherparty,200000000,D2016Q1Mar2016_srt_LitigationCaseAxis_mrk_GileadPatentCaseMember
us-gaap:litigationsettlementamountawardedfromotherparty,2540000000,D2016Q4Dec_srt_LitigationCaseAxis_mrk_GileadPatentCaseMember
us-gaap:litigationsettlementamountawardedtootherparty,4300000,D2018Q2April9_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember
us-gaap:litigationsettlementamountawardedtootherparty,27300000,FD2014Q4YTD_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_OnjLitigationMember
us-gaap:longtermdebtnoncurrent,21353000000,FI2017Q4
us-gaap:longtermdebtnoncurrent,19936000000,FI2018Q3
us-gaap:losscontingencyclaimsdismissednumber,650,D2014Q1Mar_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencyclaimsdismissednumber,1055,FD2018Q3YTD_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,275,FI2018Q3_srt_LitigationCaseAxis_mrk_CaliforniaStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,3,FI2018Q3_srt_LitigationCaseAxis_mrk_FederalMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,2610,FI2018Q3_srt_LitigationCaseAxis_mrk_NewJerseyMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,4,FI2018Q3_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,8,FI2018Q3_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_JanuviaMember
us-gaap:losscontingencypendingclaimsnumber,1,FI2018Q3_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_srt_StatementGeographicalAxis_stpr_CA
us-gaap:losscontingencypendingclaimsnumber,1,FI2018Q3_srt_LitigationCaseAxis_mrk_OtherStateCourtMember_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember_srt_StatementGeographicalAxis_stpr_MA
us-gaap:losscontingencypendingclaimsnumber,3955,FI2018Q3_srt_ProductOrServiceAxis_mrk_FosamaxMember
us-gaap:losscontingencypendingclaimsnumber,3950,FI2018Q3_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_FemurFractureLitigationMember
us-gaap:losscontingencypendingclaimsnumber,4,FI2018Q3_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_OnjLitigationMember
us-gaap:losscontingencypendingclaimsnumber,1285,FI2018Q3_srt_ProductOrServiceAxis_mrk_JanuviaMember
us-gaap:losscontingencypendingclaimsnumber,50,FI2018Q3_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember
us-gaap:losscontingencypendingclaimsnumber,40,FI2018Q3_srt_ProductOrServiceAxis_mrk_PropeciaProscarMember
us-gaap:marketablesecuritiescurrent,2406000000,FI2017Q4
us-gaap:marketablesecuritiescurrent,2459000000,FI2018Q3
us-gaap:marketablesecuritiesnoncurrent,12125000000,FI2017Q4
us-gaap:marketablesecuritiesnoncurrent,7606000000,FI2018Q3
us-gaap:minorityinterest,233000000,FI2017Q4
us-gaap:minorityinterest,234000000,FI2018Q3
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,3000000,FD2017Q3QTD
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,3000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,10000000,FD2017Q3YTD
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,10000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,11000000,FD2018Q3QTD
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,11000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,21000000,FD2018Q3YTD
us-gaap:minorityinterestdecreasefromdistributionstononcontrollinginterestholders,21000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netcashprovidedbyusedininvestingactivities,2737000000,FD2017Q3YTD
us-gaap:netcashprovidedbyusedininvestingactivities,2136000000,FD2018Q3YTD
us-gaap:netcashprovidedbyusedinoperatingactivities,2432000000,FD2017Q3YTD
us-gaap:netcashprovidedbyusedinoperatingactivities,7330000000,FD2018Q3YTD
us-gaap:netincomeloss,3440000000,FD2017Q3YTD
us-gaap:netincomeloss,3440000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:netincomeloss,1950000000,FD2018Q3QTD
us-gaap:netincomeloss,1950000000,FD2018Q3QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:netincomeloss,1950000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:netincomeloss,4393000000,FD2018Q3YTD
us-gaap:netincomeloss,4384000000,FD2018Q3YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:netincomeloss,4393000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:netincomelossattributabletononcontrollinginterest,5000000,FD2017Q3QTD
us-gaap:netincomelossattributabletononcontrollinginterest,5000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netincomelossattributabletononcontrollinginterest,16000000,FD2017Q3YTD
us-gaap:netincomelossattributabletononcontrollinginterest,16000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netincomelossattributabletononcontrollinginterest,8000000,FD2018Q3QTD
us-gaap:netincomelossattributabletononcontrollinginterest,8000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:netincomelossattributabletononcontrollinginterest,22000000,FD2018Q3YTD
us-gaap:netincomelossattributabletononcontrollinginterest,22000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:newaccountingpronouncementorchangeinaccountingprinciplecumulativeeffectofchangeonequityornet,48000000,I2018Q1Jan1
us-gaap:newaccountingpronouncementorchangeinaccountingprinciplecumulativeeffectofchangeonequityornet,322000000,I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:noncontrollinginterestincreasefrombusinesscombination,25000000,FD2017Q3YTD
us-gaap:noncontrollinginterestincreasefrombusinesscombination,25000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:numberofinterestratederivativesheld,22,FI2018Q3
us-gaap:numberofinterestratederivativesheld,5,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.85NotesDue2020Member
us-gaap:numberofinterestratederivativesheld,5,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.35NotesDue2022Member
us-gaap:numberofinterestratederivativesheld,4,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A2.40NotesDue2022Member
us-gaap:numberofinterestratederivativesheld,5,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member
us-gaap:numberofinterestratederivativesheld,3,FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A5.00NotesDue2019Member
us-gaap:numberofinterestratederivativesheld,4,I2018Q2May31_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A1.30NotesDue2018Member
us-gaap:numberofoperatingsegments,4,FD2018Q3YTD
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,107000000,FD2017Q3QTD
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,2000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,170000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,23000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,51000000,FD2017Q3YTD
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,27000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,283000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,261000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,29000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,8000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsbeforetaxattributabletoparent,113000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,150000000,FD2017Q3QTD
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,151000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,67000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,365000000,FD2017Q3YTD
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,20000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,260000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,423000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,23000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,8000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,2000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:ocibeforereclassificationsnetoftaxattributabletoparent,89000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,481000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,66000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,128000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,1000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,79000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,207000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,652000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,66000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,128000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,171000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,1000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,79000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,207000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,236000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,182000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,54000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,253000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,17000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,101000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,23000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,112000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,489000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:otherassetsnoncurrent,17000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,101000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember
us-gaap:otherassetsnoncurrent,182000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember
us-gaap:otherassetsnoncurrent,23000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MortgageBackedSecuritiesMember
us-gaap:otherassetsnoncurrent,166000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,135000000,FD2017Q3QTD
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,213000000,FD2017Q3YTD
us-gaap:othercomprehensiveincomeavailableforsalesecuritiesadjustmentnetoftaxportionattributabletopar,40000000,FD2018Q3QTD
us-gaap:othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionatt,67000000,FD2017Q3QTD
us-gaap:othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionatt,423000000,FD2017Q3YTD
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,13000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,19000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,7000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,23000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,6000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,130000000,FD2018Q3YTD
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,24000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossbeforereclassificationstax,111000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossafterreclassificationandtaxparent,27000000,FD2018Q3QTD
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossafterreclassificationandtaxparent,223000000,FD2018Q3YTD
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossbeforereclassificationandtax,29000000,FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossbeforereclassificationandtax,113000000,FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossreclassificationaftertax,6000000,FD2018Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelosscashflowhedgegainlossreclassificationaftertax,172000000,FD2018Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember
us-gaap:othercomprehensiveincomelossnetoftax,149000000,FD2017Q3QTD
us-gaap:othercomprehensiveincomelossnetoftax,149000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember
us-gaap:othercomprehensiveincomelossnetoftax,281000000,FD2017Q3YTD
us-gaap:othercomprehensiveincomelossnetoftax,281000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember
us-gaap:othercomprehensiveincomelossnetoftax,33000000,FD2018Q3YTD
us-gaap:othercomprehensiveincomelossnetoftax,33000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,149000000,FD2017Q3QTD
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,13000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,135000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,67000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,281000000,FD2017Q3YTD
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,86000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,213000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,423000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,40000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,27000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,40000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,33000000,FD2018Q3YTD
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,106000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember
us-gaap:othercomprehensiveincomelossnetoftaxportionattributabletoparent,223000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:otherinventorysupplies,201000000,FI2017Q4
us-gaap:otherinventorysupplies,202000000,FI2018Q3
us-gaap:otherliabilitiescurrent,10427000000,FI2017Q4
us-gaap:otherliabilitiescurrent,9776000000,FI2018Q3
us-gaap:otherliabilitiescurrent,9770000000,FI2018Q3_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:otherliabilitiesnoncurrent,11117000000,FI2017Q4
us-gaap:otherliabilitiesnoncurrent,100000000,FI2017Q4_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,150000000,FI2018Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,200000000,FI2018Q2_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,375000000,FI2018Q2_srt_CounterpartyNameAxis_mrk_BayerAGMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:otherliabilitiesnoncurrent,11887000000,FI2018Q3
us-gaap:otherliabilitiesnoncurrent,50000000,FI2018Q3_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_TypeOfArrangementAxis_mrk_SalesBasedMilestonesMember
us-gaap:othernoncashincomeexpense,31000000,FD2017Q3YTD
us-gaap:othernonoperatingincomeexpense,207000000,FD2017Q3QTD
us-gaap:othernonoperatingincomeexpense,351000000,FD2017Q3YTD
us-gaap:othernonoperatingincomeexpense,172000000,FD2018Q3QTD
us-gaap:othernonoperatingincomeexpense,512000000,FD2018Q3YTD
us-gaap:paymentforcontingentconsiderationliabilityinvestingactivities,175000000,FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_mrk_AfferentPharmaceuticalsMember
us-gaap:paymentsforproceedsfromotherinvestingactivities,150000000,FD2018Q3YTD
us-gaap:paymentsforrepurchaseofcommonstock,2312000000,FD2017Q3YTD
us-gaap:paymentsforrepurchaseofcommonstock,3158000000,FD2018Q3YTD
us-gaap:paymentsforrestructuring,705000000,FD2018Q3YTD
us-gaap:paymentsforrestructuring,535000000,FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:paymentsforrestructuring,170000000,FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:paymentsofdividendscommonstock,3884000000,FD2017Q3YTD
us-gaap:paymentsofdividendscommonstock,3895000000,FD2018Q3YTD
us-gaap:paymentstoacquireadditionalinterestinsubsidiaries,18000000,FD2017Q4QTD_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:paymentstoacquirebusinessesgross,358000000,D2017Q1Mar_us-gaap_BusinessAcquisitionAxis_mrk_ValleeSAMember
us-gaap:paymentstoacquirebusinessesgross,502000000,D2018Q2June_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:paymentstoacquirebusinessesgross,378000000,D2018Q2June_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:paymentstoacquirebusinessesnetofcashacquired,347000000,FD2017Q3YTD
us-gaap:paymentstoacquirebusinessesnetofcashacquired,372000000,FD2018Q3YTD
us-gaap:paymentstoacquireintangibleassets,750000000,D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:paymentstoacquireintangibleassets,325000000,D2019Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,200000000,D2020Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,125000000,D2021Q1Jan01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,650000000,D2021Q1Mar01-Jan31_srt_CounterpartyNameAxis_mrk_EisaiMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:paymentstoacquireintangibleassets,250000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:paymentstoacquiremarketablesecurities,8397000000,FD2017Q3YTD
us-gaap:paymentstoacquiremarketablesecurities,6899000000,FD2018Q3YTD
us-gaap:paymentstoacquireproductiveassets,1173000000,FD2017Q3YTD
us-gaap:paymentstoacquireproductiveassets,1686000000,FD2018Q3YTD
us-gaap:proceedsfromdivestitureofbusinesses,65000000,D2018Q2April_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_mrk_C3iMember
us-gaap:proceedsfromrepaymentsofshorttermdebt,1962000000,FD2017Q3YTD
us-gaap:proceedsfromrepaymentsofshorttermdebt,2294000000,FD2018Q3YTD
us-gaap:proceedsfromsalematurityandcollectionsofinvestments,12533000000,FD2017Q3YTD
us-gaap:proceedsfromsalematurityandcollectionsofinvestments,11243000000,FD2018Q3YTD
us-gaap:proceedsfromsaleofintangibleassets,60000000,FD2017Q3YTD
us-gaap:proceedsfromsaleofintangibleassets,81000000,FD2018Q3YTD
us-gaap:proceedsfromstockoptionsexercised,481000000,FD2017Q3YTD
us-gaap:proceedsfromstockoptionsexercised,461000000,FD2018Q3YTD
us-gaap:productionrelatedimpairmentsorcharges,122000000,FD2018Q3QTD_srt_CounterpartyNameAxis_mrk_SamsungMember
us-gaap:profitloss,3456000000,FD2017Q3YTD
us-gaap:profitloss,1958000000,FD2018Q3QTD
us-gaap:profitloss,4415000000,FD2018Q3YTD
us-gaap:propertyplantandequipmentnet,12439000000,FI2017Q4
us-gaap:propertyplantandequipmentnet,12755000000,FI2018Q3
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,7000000,FD2017Q3QTD
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,14000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,24000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,146000000,FD2017Q3YTD
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,159000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodbeforetaxattributabletoparent,73000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,1000000,FD2017Q3QTD
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,9000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,16000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,84000000,FD2017Q3YTD
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,103000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodnetoftaxattributabletoparent,47000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodtax,6000000,FD2017Q3QTD
us-gaap:reclassificationfromaocicurrentperiodtax,5000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodtax,8000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:reclassificationfromaocicurrentperiodtax,62000000,FD2017Q3YTD
us-gaap:reclassificationfromaocicurrentperiodtax,56000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:reclassificationfromaocicurrentperiodtax,26000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:repaymentsoflongtermdebt,301000000,FD2017Q3YTD
us-gaap:repaymentsoflongtermdebt,3007000000,FD2018Q3YTD
us-gaap:researchanddevelopmentexpense,4413000000,FD2017Q3QTD
us-gaap:researchanddevelopmentexpense,4208000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,2350000000,FD2017Q3QTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:researchanddevelopmentexpense,8024000000,FD2017Q3YTD
us-gaap:researchanddevelopmentexpense,7399000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,2350000000,FD2017Q3YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:researchanddevelopmentexpense,2350000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_AstraZenecaMember
us-gaap:researchanddevelopmentexpense,2068000000,FD2018Q3QTD
us-gaap:researchanddevelopmentexpense,1855000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,7538000000,FD2018Q3YTD
us-gaap:researchanddevelopmentexpense,6878000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:researchanddevelopmentexpense,1400000000,FD2018Q3YTD_srt_CounterpartyNameAxis_mrk_EisaiMember
us-gaap:researchanddevelopmentexpense,344000000,FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_mrk_ViralyticsMember
us-gaap:restrictedcashandcashequivalents,4000000,FI2017Q4
us-gaap:restrictedcashandcashequivalents,2000000,FI2018Q3
us-gaap:restructuringandrelatedcostcostincurredtodate1,14000000000,FI2018Q3
us-gaap:restructuringandrelatedcostexpectedcost1,50000000,FI2018Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember
us-gaap:restructuringandrelatedcostincurredcost,180000000,FD2017Q3QTD
us-gaap:restructuringandrelatedcostincurredcost,25000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,5000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,20000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,153000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,100000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,53000000,FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,6000000,FD2017Q3QTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,100000000,FD2017Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,74000000,FD2017Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,605000000,FD2017Q3YTD
us-gaap:restructuringandrelatedcostincurredcost,121000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,52000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,69000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,11000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,7000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,4000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,470000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,302000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,168000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,3000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,61000000,FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,302000000,FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,242000000,FD2017Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,169000000,FD2018Q3QTD
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,5000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,171000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,137000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,34000000,FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,137000000,FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,40000000,FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,508000000,FD2018Q3YTD
us-gaap:restructuringandrelatedcostincurredcost,11000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,10000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember
us-gaap:restructuringandrelatedcostincurredcost,13000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,494000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember
us-gaap:restructuringandrelatedcostincurredcost,392000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,102000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,2000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_mrk_AcceleratedDepreciationMember
us-gaap:restructuringandrelatedcostincurredcost,1000000,FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostincurredcost,392000000,FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringandrelatedcostincurredcost,126000000,FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,205,FD2017Q3QTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,1225,FD2017Q3YTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,525,FD2018Q3QTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminated,1870,FD2018Q3YTD
us-gaap:restructuringandrelatedcostnumberofpositionseliminatedinceptiontodate,45220,FI2018Q3
us-gaap:restructuringcharges,153000000,FD2017Q3QTD
us-gaap:restructuringcharges,153000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,470000000,FD2017Q3YTD
us-gaap:restructuringcharges,470000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,171000000,FD2018Q3QTD
us-gaap:restructuringcharges,171000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringcharges,494000000,FD2018Q3YTD
us-gaap:restructuringcharges,494000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember
us-gaap:restructuringreserve,747000000,FI2017Q4
us-gaap:restructuringreserve,619000000,FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringreserve,128000000,FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:restructuringreserve,573000000,FI2018Q3
us-gaap:restructuringreserve,476000000,FI2018Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember
us-gaap:restructuringreserve,97000000,FI2018Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember
us-gaap:retainedearningsaccumulateddeficit,41350000000,FI2017Q4
us-gaap:retainedearningsaccumulateddeficit,42189000000,FI2018Q3
us-gaap:retainedearningsaccumulateddeficit,42174000000,FI2018Q3_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:retainedearningsaccumulateddeficit,266000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_mrk_AccountingStandardUpdate201802Member
us-gaap:retainedearningsaccumulateddeficit,5000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
us-gaap:retainedearningsaccumulateddeficit,8000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member
us-gaap:retainedearningsaccumulateddeficit,54000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member
us-gaap:retainedearningsaccumulateddeficit,322000000,I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember
us-gaap:revenues,10325000000,FD2017Q3QTD
us-gaap:revenues,69000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,7000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,63000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,10256000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,70000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,70000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,80000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,80000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,59000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,59000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,27000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,30000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,63000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,122000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,185000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,6000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,88000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,153000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,192000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,345000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,9000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,119000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,128000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,41000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,50000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,91000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,7000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,59000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,88000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,49000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,30000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,41000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,72000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,48000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,53000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,484000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,191000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,675000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,110000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,45000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,155000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,93000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,66000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,159000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,143000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,167000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,310000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,197000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,316000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,513000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,598000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,414000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1012000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,604000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,442000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1047000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,518000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,655000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,65000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,42000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,78000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,162000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,160000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,54000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,214000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,266000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,688000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,952000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,174000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,229000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,68000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,73000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,419000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,100000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,519000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,214000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,214000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,127000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,179000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,219000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,219000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,16000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,145000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,161000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,68000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,68000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,148000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,142000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,228000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,241000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,468000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,65000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,255000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,320000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,139000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,234000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4587000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,290000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,4197000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,100000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,5669000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,710000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,4959000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,9156000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,100000000,FD2017Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,775000000,FD2017Q3QTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,4594000000,FD2017Q3QTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,5732000000,FD2017Q3QTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,318000000,FD2017Q3QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,1112000000,FD2017Q3QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,585000000,FD2017Q3QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,2941000000,FD2017Q3QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,13000000,FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
us-gaap:revenues,29689000000,FD2017Q3YTD
us-gaap:revenues,400000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,73000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,327000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,29289000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,221000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,221000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,272000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,272000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,171000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,171000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,72000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,78000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,150000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,162000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,333000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,495000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,17000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,310000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,327000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,483000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,595000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1078000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,15000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,345000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,360000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,148000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,141000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,290000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,191000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,19000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,210000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,257000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,413000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,104000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,128000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,232000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,7000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,173000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,180000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1195000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,481000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1675000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,367000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,503000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,268000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,177000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,445000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,422000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,474000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,896000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,640000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,933000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1572000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1646000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1153000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2799000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1522000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,990000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2512000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,359000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1457000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1816000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,16000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,250000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,266000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,220000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,237000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,458000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,425000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,148000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,573000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,876000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2140000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3017000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,392000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,166000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,558000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,7000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,199000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,206000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1058000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,215000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1273000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,651000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,651000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,377000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,148000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,525000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,602000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,602000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,28000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,522000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,550000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,4000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,194000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,198000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,114000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,451000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,565000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,683000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,680000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1363000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,298000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,723000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1021000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,356000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,191000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,547000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,13023000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,842000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,11887000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,294000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,16266000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,2052000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,14214000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2894000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,26101000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,294000000,FD2017Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,2320000000,FD2017Q3YTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,13096000000,FD2017Q3YTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,16593000000,FD2017Q3YTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,1081000000,FD2017Q3YTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,3164000000,FD2017Q3YTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,1654000000,FD2017Q3YTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,8374000000,FD2017Q3YTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,157000000,FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
us-gaap:revenues,500000000,FD2017Q4YTD_srt_CounterpartyNameAxis_mrk_BayerAGMember_srt_ProductOrServiceAxis_mrk_AdempasMember
us-gaap:revenues,10794000000,FD2018Q3QTD
us-gaap:revenues,60000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,20000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,39000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,10734000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,94000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,94000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,33000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,15000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,49000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,84000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,84000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,23000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,43000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,66000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,96000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,120000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,217000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,77000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,79000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,153000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,207000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,361000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,4000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,103000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,55000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,40000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,95000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,44000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,6000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,50000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,52000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,123000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,26000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,34000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,60000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,42000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,45000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,740000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,308000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1048000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,133000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,53000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,186000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,74000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,62000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,123000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,151000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,275000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,225000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,339000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,563000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,498000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,429000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,927000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1109000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,780000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1889000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,30000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,13000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,43000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,153000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,508000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,660000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,7000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,64000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,89000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,99000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,188000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,193000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,41000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,234000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,317000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,666000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,980000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,160000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,54000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,214000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,71000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,72000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,429000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,96000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,525000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,135000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,135000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,134000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,57000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,191000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,210000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,210000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,161000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,46000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,46000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,92000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,92000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,18000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,86000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,104000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,9000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,157000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,165000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,56000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,54000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5010000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,306000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,4649000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,55000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,5725000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,715000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,5010000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1021000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,9658000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,55000000,FD2018Q3QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,761000000,FD2018Q3QTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,5030000000,FD2018Q3QTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,5764000000,FD2018Q3QTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,319000000,FD2018Q3QTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,1178000000,FD2018Q3QTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,622000000,FD2018Q3QTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,2884000000,FD2018Q3QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,10793000000,FD2018Q3QTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:revenues,31296000000,FD2018Q3YTD
us-gaap:revenues,66000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember
us-gaap:revenues,101000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,31230000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember
us-gaap:revenues,238000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,238000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AdempasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,88000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,37000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,125000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AlliancerevenueLynparzaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,249000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,249000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ArcoxiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,258000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,258000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_AtozetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,76000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,115000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,191000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BelsomraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,272000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,389000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,661000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_BridionMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,10000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,247000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,257000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CancidasMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,541000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,689000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1230000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CompanionAnimalsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,18000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,330000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,348000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CozaarHyzaarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,150000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,137000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,287000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_CubicinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,128000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,21000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,149000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_DuleraMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,239000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,157000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,396000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_EmendMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,83000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,115000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,198000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FollistimAqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,155000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,159000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_FosamaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1422000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,894000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2317000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_GardasilGardasil9Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,375000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,160000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,535000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ImplanonNexplanonMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,252000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,185000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,437000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_InvanzMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,383000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,477000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,860000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_IsentressIsentressHDMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,625000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1067000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1693000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanumetMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1466000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1291000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2756000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_JanuviaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2906000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2114000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,5020000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_KeytrudaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,49000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,29000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,78000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LenvimaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,383000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1563000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,1946000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_LivestockMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,8000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,266000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,274000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NasonexMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,257000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,294000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,551000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NoxafilMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,550000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,135000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,686000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_NuvaringMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,877000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,2150000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3023000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_OtherPharmaceuticalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,394000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,192000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,586000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_Pneumovax23Member_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,6000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,206000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,212000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_PrimaxinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1097000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,246000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1343000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ProQuadMMRIIVarivaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,459000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,459000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RemicadeMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,384000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,540000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_RotateqMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,673000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,673000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SimponiMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,16000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,505000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,521000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_SingulairMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,3000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,156000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,159000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_TemodarMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,11000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,402000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,414000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_VytorinMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,8000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,339000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,347000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZepatierMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,34000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,662000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,696000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZetiaMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,16000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,147000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,163000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_mrk_ZostavaxMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,13324000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,924000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,12206000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,194000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,17906000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,2252000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,15653000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,1000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_StatementGeographicalAxis_mrk_InternationalMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,3176000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_AnimalHealthsegmentMember
us-gaap:revenues,27859000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_mrk_PharmaceuticalsegmentMember
us-gaap:revenues,195000000,FD2018Q3YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember
us-gaap:revenues,2353000000,FD2018Q3YTD_srt_StatementGeographicalAxis_country_JP
us-gaap:revenues,13425000000,FD2018Q3YTD_srt_StatementGeographicalAxis_country_US
us-gaap:revenues,17871000000,FD2018Q3YTD_srt_StatementGeographicalAxis_mrk_InternationalMember
us-gaap:revenues,786000000,FD2018Q3YTD_srt_StatementGeographicalAxis_mrk_OtherCountriesMember
us-gaap:revenues,3766000000,FD2018Q3YTD_srt_StatementGeographicalAxis_srt_AsiaPacificMember
us-gaap:revenues,1748000000,FD2018Q3YTD_srt_StatementGeographicalAxis_srt_LatinAmericaMember
us-gaap:revenues,9218000000,FD2018Q3YTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember
us-gaap:revenues,31266000000,FD2018Q3YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
us-gaap:sellinggeneralandadministrativeexpense,2459000000,FD2017Q3QTD
us-gaap:sellinggeneralandadministrativeexpense,7432000000,FD2017Q3YTD
us-gaap:sellinggeneralandadministrativeexpense,2443000000,FD2018Q3QTD
us-gaap:sellinggeneralandadministrativeexpense,7459000000,FD2018Q3YTD
us-gaap:sharebasedcompensation,76000000,FD2017Q3QTD
us-gaap:sharebasedcompensation,232000000,FD2017Q3YTD
us-gaap:sharebasedcompensation,91000000,FD2018Q3QTD
us-gaap:sharebasedcompensation,261000000,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,1000000,FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,5000000,FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,855000,FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,7000000,FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,63.62,FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,63.96,FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,56.70,FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgr,58.19,FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpecteddividen,0.036,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpecteddividen,0.034,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatil,0.178,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatil,0.191,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinteres,0.020,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinteres,0.028,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod,4000000,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod,3000000,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverag,7.04,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverag,8.19,FD2018Q3YTD
us-gaap:sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedavera,63.96,FD2017Q3YTD
us-gaap:sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedavera,57.72,FD2018Q3YTD
us-gaap:stockholdersequity,34336000000,FI2017Q4
us-gaap:stockholdersequity,32422000000,FI2018Q3
us-gaap:stockholdersequitybeforetreasurystock,78130000000,FI2017Q4
us-gaap:stockholdersequitybeforetreasurystock,78588000000,FI2018Q3
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,40308000000,FI2016Q4
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,338000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39939000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,220000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,44133000000,FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39712000000,FI2017Q2
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,75000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39776000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,249000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,45046000000,FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,38499000000,FI2017Q3
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,210000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39823000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,251000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,43701000000,FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,34569000000,FI2017Q4
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39902000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,233000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,41350000000,FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,32766000000,FI2018Q2
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,65000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39741000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,237000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,41523000000,FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,32656000000,FI2018Q3
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,92000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,39762000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,1788000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,234000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember
us-gaap:stockholdersequityincludingportionattributabletononcontrollinginterest,42189000000,FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember
us-gaap:stockholdersequityother,116000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityother,140000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember
us-gaap:stockholdersequityothershares,1000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:stockholdersequityothershares,13000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:stockholdersequityothershares,5000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:stockholdersequityothershares,15000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:taxadjustmentssettlementsandunusualprovisions,88000000,FD2017Q3YTD
us-gaap:tradingsecurities,172000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:tradingsecurities,14359000000,FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:tradingsecurities,14531000000,FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:tradingsecurities,196000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:tradingsecurities,9869000000,FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:tradingsecurities,10065000000,FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember
us-gaap:treasurystockshares,880491914,FI2017Q4
us-gaap:treasurystockshares,918364126,FI2018Q3
us-gaap:treasurystocksharesacquired,2000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystocksharesacquired,36000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystocksharesacquired,16000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystocksharesacquired,53000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalue,43794000000,FI2017Q4
us-gaap:treasurystockvalue,46166000000,FI2018Q3
us-gaap:treasurystockvalueacquiredcostmethod,159000000,FD2017Q3QTD
us-gaap:treasurystockvalueacquiredcostmethod,159000000,FD2017Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalueacquiredcostmethod,2312000000,FD2017Q3YTD
us-gaap:treasurystockvalueacquiredcostmethod,2312000000,FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalueacquiredcostmethod,996000000,FD2018Q3QTD
us-gaap:treasurystockvalueacquiredcostmethod,996000000,FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:treasurystockvalueacquiredcostmethod,3158000000,FD2018Q3YTD
us-gaap:treasurystockvalueacquiredcostmethod,3158000000,FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember
us-gaap:unrecognizedtaxbenefitsdecreasesresultingfromsettlementswithtaxingauthorities,234000000,FD2017Q3QTD_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember
us-gaap:unrecognizedtaxbenefitsdecreasesresultingfromsettlementswithtaxingauthorities,234000000,FD2017Q3YTD_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_InternalRevenueServiceIRSMember
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,19000000,FD2017Q3YTD
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,16000000,FD2018Q3QTD
us-gaap:weightedaveragenumberdilutedsharesoutstandingadjustment,14000000,FD2018Q3YTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2727000000,FD2017Q3QTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2754000000,FD2017Q3YTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2678000000,FD2018Q3QTD
us-gaap:weightedaveragenumberofdilutedsharesoutstanding,2694000000,FD2018Q3YTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2727000000,FD2017Q3QTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2735000000,FD2017Q3YTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2662000000,FD2018Q3QTD
us-gaap:weightedaveragenumberofsharesoutstandingbasic,2680000000,FD2018Q3YTD
